The Tennessee Center for AIDS Research CFAR (CFAR) is located in the Southeastern US, the region with both the greatest number of new HIV-1 infections, and of persons living with HIV. Under the leadership of Dr. Simon Mallal, recruited to Vanderbilt (VU) to lead this Center, the Tennessee CFAR is a three-way partnership between a research-intensive institution (VU), a historically black medical college (Meharry Medical College, MMC), and an academically engaged state health department (Tennessee Department of Health, TDH). This CFAR's institutional and community environment is rich in opportunity, and with a culture of engagement and collaboration. The Clinical Sciences Core (CSC) will fill major gaps in the local research environment, and in so doing support the mission of the Tennessee CFAR to reduce the burden of HIV/AIDS, as well as other goals of the nationwide CFAR program. This will be accomplished through three Specific Aims: 1) To propel the use of robust observational databases for hypothesis-driven clinical and translational research across disciplines focused on reducing the overall burden of HIV/AIDS; 2) To support investigators with research projects that require access to study volunteers, and associated biological specimens; 3) To create new opportunities for clinical and translational research at MMC, as well as cross-institutional opportunities, and to facilitate MMC investigator access to such opportunities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI110527-04
Application #
9631978
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Beaubien, Candice M
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Buchanan, Ashley L; Vermund, Sten H; Friedman, Samuel R et al. (2018) Assessing Individual and Disseminated Effects in Network-Randomized Studies. Am J Epidemiol 187:2449-2459
Kim, Whan B; Worley, Brandon; Holmes, James et al. (2018) Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol 79:1150-1152
Hulgan, Todd (2018) Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update. Curr HIV/AIDS Rep 15:223-232
Trubiano, Jason A; Grayson, M Lindsay; Phillips, Elizabeth J et al. (2018) Antibiotic allergy testing improves antibiotic appropriateness in patients with cancer. J Antimicrob Chemother 73:3209-3211
Redwood, A J; Pavlos, R K; White, K D et al. (2018) HLAs: Key regulators of T-cell-mediated drug hypersensitivity. HLA 91:3-16
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Rajagopala, Seesandra V; Singh, Harinder; Patel, Mira C et al. (2018) Cotton rat lung transcriptome reveals host immune response to Respiratory Syncytial Virus infection. Sci Rep 8:11318
Dong, Xin-Hong; Ho, Meng-Hsuan; Liu, Bindong et al. (2018) Role of Porphyromonas gingivalis outer membrane vesicles in oral mucosal transmission of HIV. Sci Rep 8:8812
Wanjalla, Celestine N; McDonnell, Wyatt J; Koethe, John R (2018) Adipose Tissue T Cells in HIV/SIV Infection. Front Immunol 9:2730
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504

Showing the most recent 10 out of 126 publications